Latest updates for Ibrx
Fresh curated links around IBRX are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
- ImmunityBio: ANKTIVA's Commercial Momentum Supports A Buy
- ImmunityBio: Intriguing Progress, If Not (Yet) Commercially - Still A Hold
- Inhibrx Biosciences: The Whole Story Rides On INBRX-106
Post angles to try
Fresh articles and ideas
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
ImmunityBio: Intriguing Progress, If Not (Yet) Commercially - Still A Hold
BRC Group outlines plan to fund over $300M of 2026 maturities while reporting $66M operating adjusted EBITDA
iShares iBonds Dec 2054 Term Treasury ETF declares monthly distribution of $0.0933
Bally's Intralot S.A. (IRLTF) Q2 2026 Earnings Call Transcript
IGLB vs SCHQ: Corporate Bonds Beat Treasuries on Yield and Trailing Returns
IGLB's 5.40% dividend yield and stronger 5-year performance make it compelling for income investors seeking long-duration exposure.
US brokerage giant Interactive Brokers adds Bucharest Stock Exchange companies on its platform
Interactive Brokers, the American brokerage giant with more than 5 million clients, USD 775 billion in assets, and more than 4 million trades processed daily across 170 markets, ha...
iShares iBonds 2026 Term High Yield and Income ETF declares monthly distribution of $0.0793
iShares iBonds Dec 2055 Term Treasury ETF declares monthly distribution of $0.0962
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.